Summary
Doxorubicin (adriamycin) has a very wide antitumour spectrum, compared with other anticancer drugs; however, except for Hodgkin’s disease, it is not associated with curative chemotherapy. Doxorubicin has been in clinical use for more than 2 decades, and only recently has it been recognised that the cytotoxic effect is produced at the cellular level by multiple mechanisms which have not yet been conclusively identified. Key factors are a combination of doxorubicin-induced free radical formation due to metabolic activation, deleterious actions at the level of the membrane, and drug-intercalation into DNA.
Multiple aspects of the clinical pharmacokinetics of this drug have been described. Wide interpatient variations in plasma pharmacokinetics have been noted, but without firm relation to clinical outcome. An apparent volume of distribution of approximately 25 L/kg points to extensive uptake by tissues. Up to several weeks after administration, significant concentrations of doxorubicin have been found in haematopoietic cells and in several other tissues. The maximum cellular doxorubicin concentrations reached in vivo remain significantly below those at which all clonogenic leukaemic cells are killed in vitro.
Doxorubicin has been administered as frequent (weekly) low doses, single high doses, and as a continuous infusion. The optimal schedule with respect to tumour cytotoxicity and dose-limiting side effects such as myelosuppression or cardiotoxicity, has never been investigated in a prospective, randomised manner. Clinical trials large enough to study optimal, and possibly individualised, doxorubicin chemotherapy need to be performed.
This review summarises pharmacological and pharmacodynamic data of doxorubicin, and discusses these in relation to possible improvement of its therapeutic index. Furthermore, drug interactions, dose-response relationships, mechanisms of action, multidrug resistance, and treatment scheduling are discussed in the perspective of the development of novel treatment strategies.
Similar content being viewed by others
References
Arcamone F. Discovery and development of doxorubicin. In Arcamone F (Ed.) Doxorubicin, anticancer antibiotics, pp. 1–48, Academic Press, New York, 1981
Arcamone F, Cassinelli G, Fantini G, et al. Doxorubicin, 14-hydroxy-daunomycin, a new antitumor antibiotic from S. peucetius. Biotechnology and Bioengineering 11: 1101–1104, 1969
Arcamone F, Di Marco A, Gaetani M, Scotti T. Isolation and antitumour activity of an antibiotic, originated from Streptomyces species. Giornale Microbiologia 9: 83–90, 1961
Aszalos A. Analysis of antitumor antibiotics by high pressure liquid chromatography. Journal of Liquid Chromatography 7: 69–125, 1984
Awidi AS, Tarawneh MS, Shubair KS, et al. Acute leukemia in pregnancy: report of five cases treated with a combination which included a low dose of doxorubicin. European Journal of Cancer and Clinical Oncology 19: 881–884, 1983
Bachur NR, Steele M, Meriwether ND, et al. Cellular pharmacodynamics of several anthracycline antibiotics. Journal of Medicinal Chemistry 19: 651–654, 1976
Bailleul F, Levi F, Metzger G, et al. Chronotherapy of advanced breast cancer with continuous doxorubicin infusion via an implantable programmable device. Proceedings of the American Association for Cancer Research 28: Abstract no. 771, 1987
Balkwill FR, Moodie EM. Positive interactions between human interferon and cyclophosphamide or doxorubicin in a human tumor model system. Cancer Research 44: 904–908, 1984
Barranco SC. Cellular and molecular effects of doxorubicin on dividing and nondividing cells. Pharmacology and Therapeutics 24: 303–319, 1984
Baurain R, Deprez-De Campeneere, Zenebergh A, Trouet A. Plasma levels of doxorubicin after iv bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Cancer Chemotherapy and Pharmacology 9: 93–96, 1982
Benjamin RS, Riggs CE, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Research 37: 1416–1420, 1977
Benjamin RS, Wiernik PH, Bachur NR. Doxorubicin, chemotherapy, efficacy, safety and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33: 19–27, 1974
Benvenuto JA, Adams SC, Vyas HM, Anderson RW. Pharmaceutical issues in infusion chemotherapy stability and compatibility. In Lokich JJ (Ed.) Cancer chemotherapy by infusion, pp. 100–113, Precept Press, Chicago, 1987
Berens ME, Saito T, Welander CE, Modest EJ. Antitumor activity of new anthracycline analogues in combination with interferon alfa. Cancer Chemotherapy and Pharmacology 19: 301–306, 1987
Biedler JL, Riehm H. Cellular resistance to actinomycin-D in Chinese hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies. Cancer Research 30: 1174–1184, 1970
Bigotte L, Arvidson B, Olsson Y. Cytofluorescence localization of adriamycin in the nervous system, I: distribution of the drug in the central nervous system of normal adult mice after intravenous injection. Acta Neuropathologica (Berlin) 57: 121–129, 1982
Billingham ME, Mason JW, Bristow MR, Daniels KR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatment Reports 62: 865–872, 1978
Bolanowska W, Gessner T. Body residue and metabolism of adriamycin and daunorubicin in control and phenobarbital-pretreated mice. Xenobiotica 12: 125, 1982
Boston RC, Philips DR. Evidence of possible dose-dependent doxorubicin plasma kinetics in man. Cancer Treatment Reports 67: 63–69, 1983
Bouma J, Beijnen JH, Bult A, Underberg WJM. Anthracycline antitumor agents: a review of physico-chemical and analytical properties as well as stability. Pharmaceutisch Weekblad, Scientific Edition 8: 109–133, 1986
Brade WP, Freireich EJ, Goldin A. Dose-response relationship in experimental and clinical oncology. Cancer Treatment Reviews 11: 279–283, 1984
Brenner DE, Wiernik PH, Wesley M, Bachur NR. Acute doxorubicin toxicity: relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer 53: 1042–1048, 1984
Bruce WR, Meeker BE, Valeriote FA. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. Journal of the National Cancer Institute 37: 233–245, 1960
Carr B, Thall A, Doroshow JH. Doxorubicin inhibits the binding of 125I-epidermal growth factor to rat hepatocytes and inhibits EGF-induced DNA-synthesis. Proceedings of the American Association for Cancer Research 27: Abstract 969, 1986
Celio LA, DiGregorio GJ, Ruch E, et al. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. European Journal of Clinical Pharmacology 24: 261–266, 1983
Chan KK, Chlebowski RT, Tong M, et al. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Research 40: 1263–1268, 1980
Chan KK, Cohen JL, Gross JF, et al. Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treatment Reports 62: 1161–1171, 1978
Chang P, Riggs CE, Scheerer MT, et al. Combination chemotherapy with adriamycin and streptozotocin, II: clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin. Clinical Pharmacology and Therapeutics 20: 611–616, 1976
Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al. Doxorubicin (75 mg/sq. m.) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treatment Reports 68: 487–491, 1984
Creagan ET, Long HJ, Frytak S, Moertel CG. Recombinant leukocyte A interferon with doxorubicin: a phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma. Cancer 61: 19–22, 1988
Crom WR, Glynn-Barnhart AM, Rodman JH, et al. Pharmacokinetics of anticancer drugs in children. Clinical Pharmacokinetics 12: 168–213, 1987
Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M. Influence of polysorbate 80 (tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients. Cancer Chemotherapy and Pharmacology 17: 80–84, 1986
Cummings J, McArdle CS. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. British Journal of Cancer 53: 835–838, 1986
Dessypyris EN, Brenner DE, Krantz SB, Hande KR. Toxicity of adriamycin metabolites to human bone marrow erythroid and myeloid progenitors in vitro. Proceedings of the American Association for Cancer Research 25: Abstract no. 1203, 1984
DiFronzo G, Lenaz L, Bonadonna G. Distribution and excretion of adriamycin in man. Biomedicine 19: 169–171, 1973
Di Marco A. Anthracyclines in cancer chemotherapy. Drugs in Experimental and Clinical Research 9: 751–765, 1983
Di Marco A, Gaetani M, Dorigotti L, et al. Daunomycin: a new antibiotic with antitumor activity. Cancer Chemotherapy Reports 38: 31–38, 1964
Di Marco A, Gaetani M, Scarpinato B. Doxorubicin: a new antibiotic with antitumor activity. Cancer Chemotherapy Reports 53: 33–37, 1969
Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Research 43: 460–472, 1983
Egan PC, Costanza ME, Dodion P, et al. Doxorubicin and cisplatin excretion into human milk. Cancer Treatment Reports 69: 1387–1389, 1985
Ehninger G, Stocker HJ, Proksch B, Wilms K. Die Pharmacokinetik von Adriamycin und Adriamycin-Metaboliten. Klinische Wochenschrifte 58: 927–934, 1980
Eksborg S, Cedermark BJ, Strandler HS. Intrahepatic and intravenous administration of adriamycin: a comparative pharmacokinetic study in patients with malignant liver tumours. Medical Oncology and Tumor Pharmacotherapy 2: 47–52, 1985a
Eksborg S, Ehrsson H. Drug level monitoring: cytostatics. Journal of Chromatography 340: 31–72, 1985
Eksborg S, Lindfors A, Cedermark BJ. Plasma pharmacokinetics of adriamycin after intrapleural administration. Medical Oncology Tumor Pharmacotherapy 1: 193–194, 1984
Eksborg S, Strandler HS, Edsmyr F, et al. Pharmacokinetic study of iv infusions of adriamycin. European Journal of Clinical Pharmacology 28: 205–212, 1985b
Engelmann UH, Jacobi GH. Intravesical adriamycin instillations: what happens to the drug? Progress in Clinical and Biological Research 185B: 95–104, 1985
Evans WE, Crom WR, Yee Gr. Adriamycin pharmacokinetics in children. Proceedings of the American Association for Cancer Research 21: Abstract no. 176, 1980
Fassas A, Kartalis G, Klearchou N, et al. Chemotherapy for acute leukemia during pregnancy: five case reports. Nouvelle Revue Française Hematologique 26: 19–24, 1984
Foa P, Cofrancesco E, Lombardi L, et al. Non interference by heparin with the cytostatic effect of adriamyin: an in vitro study on a human promyelocytic leukaemia cell line. British Journal of Cancer 48: 735–738, 1983
Fujita H, Ogawa K, Tone H, et al. Pharmacokinetics of doxorubicin, (2″R)-4′-o-tetrahydropyranyl-adriamycin and aclarubicin. Japanese Journal of Antibiotics 39: 1321–1336, 1986
Furue H. Drug interactions with anticancer agents. Gan to Kagaku Ryoho 12: 2231–2236, 1985
Garnick MB, Weiss GR, Steele GD, et al. Clinical evaluation of long-term, continuous-infusion doxorubicin. Cancer Treatment Reports 67: 133–142, 1983
Gil P, Favre R, Durand A, et al. Time dependency of adriamycin and adriamycinol kinetics. Cancer Chemotherapy and Pharmacology 10: 120–124, 1983
Giuliani F, Casarra AM, Di Marco A. Viorologic and immunologic properties and response to daunomycin and adriamycin of a non-regressing mouse tumour derived from MSV-induced sarcoma. Biomedicine 21: 435–439, 1974
Goodman GE, Yen YP, Cox TC, Crowley J. Effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells. Cancer Research 47: 2295–2304, 1987
Goormaghtigh E, Pollakis G, Ruysschaert JM. Mitochondrial membrane modification induced by adriamycin-mediated electron transport. Biochemical Pharmacology 32: 889–893, 1983
Grace T, Kimberly P, Hacker M, Tritton T. Stimulation of growth by adriamycin. Proceedings of the American Association for Cancer Research 28: Abstract no. 1052, 1987
Green MD, Speyer JL, Stecy P, et al. ICRF-187 prevents doxorubicin cardiotoxicity: results of a randomized clinical trial. Proceedings of the American Society of Clinical Oncology 6: Abstract no. 104, 1987
Greene RF, Collins JM, Jenkins JF, et al. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Research 43: 3417–3421, 1983
Gunven P, Theve NO, Peterson C. Serum and tissue concentrations of doxorubicin after iv administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer. Cancer Chemotherapy and Pharmacology 17: 153–156, 1986
Haq MM, Legha SS, Choski J, et al. Doxorubicin-induced congestive heart failure in adults. Cancer 56: 1361–1365, 1985
Harris PA, Gross JF. Preliminary pharmacokinetic model for adriamycin. Cancer Chemotherapy Reports 59: 819–825, 1975
Hrushesky WJM. Circadian timing of cancer chemotherapy. Science 228: 73–75, 1985
Hrusehsky WJM. Circadian scheduling of chemotherapy increases ovarian patient survival and cancer responses significantly. Proceedings of the American Society of Clinical Oncology 6: Abstract no. 473, 1987
Johnston JB, Glazer RI. Cellular and molecular pharmacology of sugar amine-modified anthracyclines. In Glazer RI (Ed) Developments in cancer chemotherapy, pp. 166–176, CRC Press Inc., Boca Raton, 1984
Jones RB, Holland JF, Bhardwaj S, et al. A Phase I–II study of intensive-dose adriamycin for advanced breast cancer. Journal of Clinical Oncology 5: 172–177, 1987
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica Biophysica Acta 455: 152–162, 1976
Kalyanaraman B, Sealy RC, Sinha BK. An ESR study of the reductin of peroxides by anthracycline semiquinones. Biochimica Biophysica Acta 799: 270–285, 1984
Karp GI, Van Oeyen P, Valone F, et al. Doxorubicin in pregnancy: possible transplacental passage. Cancer Treatment Reports 67: 773–777, 1983
Kerr DJ, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemotherapy and Pharmacology 18: 239–242, 1986
Kerr DJ, Kaye SB. Aspects of cytotoxic drug penetration with particular reference to anthracyclines. Cancer Chemotherapy and Pharmacology 19: 1–5, 1987
Kovach J. Pharmacokinetic studies of anticancer agents during phase I trials. In Ames et al. (Eds) Pharmacokinetics of anticancer agents in humans, p. 450, Elsevier, Amsterdam, 1983
Krugh TR, Young MA. Daunomycin and adriamycin facilitate actinomycin D binding to poly(dA-dT)poly(dA-dT). Nature (London) 269: 627–628, 1977
Kuhlmann J. Digitalisierung bei zytostatischer Therapy. Deutsche Medizinischen Wochenschrift 106: 468–470, 1981
Kummen M, Lie KK, Lie SO. A pharmacokinetic evaluation of free and DNA-complexed adriamycin: a preliminary study in children with malignant disease. Acta Pharmacologica et Toxicologica 42: 212–218, 1978
Lahtinen R, Uusitupa M, Kuikka J, Laensimies E. Non-invasive evaluation of anthracycline-induced cardiotoxicity in man. Acta Medica Scandinavica 212: 201–206, 1982
Lane P, Vichi P, Bain DL, Tritton TR. Temperature dependence studies of adriamycin uptake and cytotoxicity. Cancer Research 47: 4038–4042, 1987
Lawrence HJ, Goodnight SH. Dimethyl sulfoxide in extravasation of anthracycline agents. Annals of Internal Medicine 98: 1026–1027, 1983
Lazo JS, Schwartz PE. Rapid distribution of adriamycin in the ascitic and pleural fluid of women with ovarian carcinomas. Gynecology-Oncology 21: 65–72, 1985
Lee YN, Chan KK, Harris IH, Cohen JL. Distribution of ADM in cancer patients, tissue uptakes, plasma concentrations after intravenous and hepatic intraarterial administration. Cancer 45: 2231–2239, 1980
Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Annals of Internal Medicine 96: 133–139, 1982
Legha SS, Hortobagyi GN, Benjamin RS. Anthracyclines. In Lokich JJ (Ed) Cancer chemotherapy by infusion, pp. 100–113, Precept Press, Chicago, 1987
Liu LF, Rowe TC, Yang KM, et al. Cleavage of DNA by mammalian DNA topoisomerase II. Journal of Biological Chemistry 258: 15365–15370, 1983
Loveless H, Arena E, Felsted RL, Bachur NR. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Research 38: 589–593, 1978
Lown JW. Molecular mechanisms of action of anticancer agents involving free radical intermediates. Advances in Free Radical Biology and Medicine 1: 225–264, 1985
Maral RJ, Jouanne M. Toxicology of daunorubicin in animals and man. Cancer Treatment Reports 65 (Suppl. 4): 9–18, 1981
Matzel W, Buechel O. Diffuse malignant mesothelioma of the pleura: intrapleural treatment with doxorubicin. Archiv für Geschwulstforschung 57: 209–218, 1987
Mimnaugh EG, Gram TE, Trush MA. Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs: characterization and effects of reactive oxygen scavengers. Journal of Pharmacology and Experimental Therapeutics 226: 806–816, 1983
Mimnaugh EG, Trush MA, Gram TE. A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity. Biochemical Pharmacology 35: 4327–4335, 1986
Mooney C, Thomas DCT, Souhami RL. Adriamycin in the treatment of relapsed primary malignant brain tumours. European Journal of Cancer and Clinical Oncology 19: 1037–1038, 1983
Moore MJ, Ehrlichman C. Therapeutic drug monitoring in oncology: problems and potential in antineoplastic therapy. Clinical Pharmacokinetics 13: 205–227, 1987
Muggia FM, Young CW, Carter SK (Eds). Anthracycline antibiotics in cancer therapy, Martinus Nijhoff Publishers, The Hague, 1982
Muindi JRF, Sinha BK, Gianni L, Myers CE. Hydroxyl radical production and DNA damage by anthracyclines. FEBS Letters 172: 226–230, 1984
Murphree SA, Tritton TR, Smith PL, Sartorelli AC. Adriamycin-induced changes in the surface of sarcoma 180 ascites cells. Biochimica Biophysica Acta 649: 317–324, 1981
Myers CE. Anthracyclines. In Pinedo & Chabner (Eds) Cancer chemotherapy, Vol. 8, pp. 52–64, Elsevier, Amsterdam, 1986
Myers CE. The anthracyclines. In Pinedo & Chabner (Eds) Cancer chemotherapy and biological response modifiers, Vol. 9, pp. 36–49, Elsevier, Amsterdam, 1987
Myers CE, Mimnaugh E, Yeh G, Sinha BK. Biochemical mechanisms of tumor cell kill by the anthracyclines. In Lown (Ed.) Anthracyclines in press, 1988
Ogawa M, Muggia FM, Rozencweig M (Eds). Adriamycin, its expanding role in cancer treatment, International congress series no. 629, Excerpta Medica, Amsterdam, 1984
Oosterbaan MJM, Dirks RJM, Vree TB, et al. Klinische pharmacokinetiek van adriamycine. Journal of Drug Research 7: 1372–1378, 1982
Oosterbaan MJM, Dirks RJM, Vree TB, Van der Kleijn E. Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites. Pharmaceutical Research 1: 33–38, 1984
Ozols RF, Hogan WM, Grotzinger KR, McCoy W, Young RC. Effects of amphotericin B on adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and in L1210 leukemia. Cancer Research 43: 959–964, 1983
Ozols RF, Young RC, Speyer JL, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Research 42: 4265–4269, 1982
Pavone-Macaluso M, Ingargiola GB, Tripi M, Lamartina M. Treatment of bladder cancer with intravesical instillation of adriamycin. Progress in Clinical and Biological Research 162B: 181–191, 1984
Peterson C, Gunven P, Theve NO. Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer. Cancer Treatment Reports 70: 947–952, 1986
Peterson C, Paul C. Pharmacokinetics of doxorubicin and daunorubicin in the treatment of acute leukemia. In Hansen HH (Ed.) Anthracyclines and cancer therapy, pp. 7–17, Excerpta Medica, Amsterdam, 1983
Pfeifle CE, Howell SB, Ashburn WL, Barone RM. Pharmacologic studies of intra-hepatic artery chemotherapy with degradable starch microspheres. Cancer Drug Delivery 3: 1–14, 1986
Potmesil M, Kirshenbaum S, Israel M, et al. Relationship of adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells. Cancer Research 43: 3528–3532, 1983
Powis G. Anticancer drug pharmacodynamics. Cancer Chemotherapy and Pharmacology 14: 177–183, 1985
Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treatment Reports 63: 827–834, 1979
Pressant CA, Metter GE, Multhauf P, et al. Effects of amphotericin B with combination chemotherapy on response rates and on survival in non-small cell carcinoma of the lung. Cancer Treatment Reports 68: 651–654, 1984
Rahman A, Roh JK, Treat J, et al. Clinical pharmacology of liposome encapsulated doxorubicin (LED) in phase I trials. Proceedings of the American Society of Clinical Oncology 6: Abstract no. 117–118, 1987
Raijmakers R, Speth P, De Witte T, et al. Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM). British Journal of Cancer 56: 123–126, 1987
Razak E, Valeriote F, Vietti T. Survival of hematopoietic and leukemia colony forming cells in vitro following the administration of daunorubicin or adriamycin. Cancer Research 32: 1496–1500, 1972
Reich SD, Bachur NR. Alterations in adriamycin efficacy by phenobarbital. Cancer Research 36: 3803–3808, 1976
Riggs CE, Bachur NR. Clinical pharmacokinetics of anthracycline antibiotics. In Ames et al. (Eds) Pharmacokinetics of anticancer agents in humans, pp. 229–278, Elsevier, Amsterdam, 1983
Riordan JR, Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacology and Therapeutics 28: 51–75, 1985
Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Research 43: 4467–4469, 1983
Rudolph R, Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. Journal of Clinical Oncology 5: 1116–1126, 1987
Russo P, Favoni RE, Zarcone D, et al. Doxorubicin cytotoxicity to P388 lymphocytic leukemia as determined by alkaline elution and established assays. Anticancer Research 6: 1297–1304, 1986b
Russo A, Tochner Z, Philips J, et al. In vivo modulation of glutathione by buthionine sulfoximine effect in marrow response to melphalan. International Journal of Radiation Oncology, Biology and Physics 12: 1187–1189, 1986a
Siegfried JA, Kennedy KA, Sartorelli AC, Tritton TR. The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. Journal of Biological Chemistry 258: 339–343, 1983
Sinha BK, Trush MA, Kennedy KA, Mimnaugh EG. Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Research 44: 2892–2896, 1984
Sinkule JA, Buchsbaum DJ, Foon K, et al. Therapeutic potential of doxorubicin/antibody/radionuclide conjugates in a B-cell lymphoma model. Proceedings of the American Association for Cancer Research 28: Abstract no. 1575, 1987
Skovsgaard T. Carrier-mediated transport of daunorubicin, adriamycin and rubidazone in Ehrlich ascites tumor cells. Biochemical Pharmacology 27: 1221–1227, 1978
Skovsgaard T, Nissen N. Membrane transport of anthracyclines. Pharmacology and Therapeutics 18: 293–311, 1982
Speth PAJ, Linssen PCM, Boezeman JBM, et al. Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography. Cytometry 6: 143–150, 1985
Speth PAJ, Linssen PCM, Boezeman, JBM, et al. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemotherapy and Pharmacology 20: 305–310, 1987b
Speth PAJ, Linssen PCM, Holdrinet RSG, Haanen C. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clinical Pharmacology and Therapeutics 41: 661–665, 1987a
Speth PAJ, Raijmakers RAP, Boezeman JBM, et al. In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic bone marrow cells. European Journal of Cancer and Clinical Oncology 24: 667–674, 1988
Sulkes A, Collins JM. Reappraisal of some dosage adjustment guidelines. Cancer Treatment Reports 71: 229–233, 1987
Takagi T, Oguro M. (2″-R)-4′-0-tetrahydropyranyladriamycin, a new anthracycline derivative: its effectiveness in lymphoid malignancies. Cancer Chemotherapy and Pharmacology 20: 151–154, 1987
Takanashi S, Bachur NR. Adriamycin metabolism in man, evidence for urinary metabolites. Drug Metabolism and Disposition 4: 79–87, 1976
Tanaka M, Yoshida S. Mechanism of the inhibition of calf thymus DNA polymerases α and β by daunomycin and adriamycin. Journal of Biochemistry 87: 911–918, 1980
Timour Q, Nony P, Lang J, et al. Doxorubicin concentration time course in the myocardium after single administration to the dog. Cancer Chemotherapy and Pharmacology 20: 267–269, 1987
Tomlinson E, Malspeis L. Concomitant absorption and stability of some anthracycline antibiotics. Journal of Pharmaceutical Sciences 71: 1121–1125, 1982
Tritton TR, Yee G. The anticancer agent can be actively cytotoxic without entering the cells. Science 217: 248–250, 1982
Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treatment Reports 67: 889–894, 1983
Twentyman PR, Fox NE, White DJ. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. British Journal of Cancer 56: 55–57, 1987
Van Hoesel QGCM. Activity and reduced toxicity of liposome entrapped doxorubicin, Ph.D. Thesis, Nijmegen University. Nijmegen, 1985
Van Hoesel QGCM, Steerenberg PA, Crommelin DJA, et al. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes. Cancer Research 44: 3698–3705, 1984
Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine 91: 710–717, 1979
Van Sloten K, Aisner J. Treatment of chemotherapy extravasation: current status. Cancer Treatment Reports 68: 939–945, 1984
Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B. Anthracyclines analogs: the past, present, and future. Cancer Chemotherapy and Pharmacology 18: 185–197, 1986
Welander CE, Morgan TM, Homesley HD, Trotta PP, Spigel RJ. Combined recombinant human interferon alpha-2 and cytotoxic agents studied in a clonogenic assay. International Journal of Cancer 35: 721–729, 1985
Widder KJ, Senyei AE, Ranney DF. In vitro release of biologically active adriamycin by magnetically responsive albumin microspheres. Cancer Research 40: 3512–3517, 1980
Wright JC. Cancer chemotherapy: past, present, and future — Part I. Journal of the National Medical Association 76: 773–784, 1984
Yeh GC, Occhipinti SJ, Phang JM, et al. Deficient glucose-6-phosphate dehydrogenase activity in adriamycin resistant tumor cell (MCF-7): a redox-dependent mechanism for adriamycin resistance. Proceedings of the American Association for Cancer Research 27: Abstract 1075, 1986
Yesair DW, Schwartzbach E, Shuck D, et al. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Research 32: 1177–1183, 1972
Young RC, Ozols RF, Myers CE. The anthracycline neoplastic drugs. New England Journal of Medicine 305: 139–153, 1981
Zubrod CG. Historic milestones in curative chemotherapy. Seminars in Oncology 6: 490–505, 1979
Zunino F, Gambetta R, Di Marco A. The inhibition in vitro of DNA polymerase and RNA polymerase by daunomycin and adriamycin. Biochemistry and Pharmacology 24: 309–311, 1975b
Zunino F, Gambetta R, Di Marco A, Zaccara A, Luoni G. A comparison of the effects of daunomycin and adriamycin on various DNA polymerases. Cancer Research 35: 754–760, 1975a
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Speth, P.A.J., van Hoesel, Q.G.C.M. & Haanen, C. Clinical Pharmacokinetics of Doxorubicin. Clin-Pharmacokinet 15, 15–31 (1988). https://doi.org/10.2165/00003088-198815010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198815010-00002